Effects of a novel Nodal-targeting monoclonal antibody in melanoma
| Autor: | Naira V. Margaryan, Alina Gilgur, Luigi Strizzi, Antonio Leonardi, Thomas M. Bodenstine, Zhila Khalkhali-Ellis, Luca Sanguigno, Annamaria Sandomenico, Annalia Focà, Menotti Ruvo, David W. Reed, Richard E.B. Seftor, Grace S. Chandler, Elisabeth A. Seftor, Mary J.C. Hendrix |
|---|---|
| Přispěvatelé: | Strizzi, Luigi, Sandomenico, Annamaria, Margaryan, Naira V., Focà, Annalia, Sanguigno, Luca, Bodenstine, Thomas M., Chandler, Grace S., Reed, David W., Gilgur, Alina, Seftor, Elisabeth A., Seftor, Richard E. B., Khalkhali Ellis, Zhila, Leonardi, Antonio, Ruvo, Menotti, Hendrix, Mary J. C. |
| Rok vydání: | 2015 |
| Předmět: |
Proto-Oncogene Proteins B-raf
Nodal Protein medicine.drug_class Nodal Breast Neoplasms Enzyme-Linked Immunosorbent Assay Smad2 Protein Monoclonal antibody Oxime Mice In vivo Cell Line Tumor antibody Oximes Animals Humans cancer Medicine Cyclin B1 Extracellular Signal-Regulated MAP Kinases Imidazole Melanoma therapy Animal Extracellular Signal-Regulated MAP Kinase business.industry Imidazoles Antibodies Monoclonal Cancer Dabrafenib Surface Plasmon Resonance medicine.disease Gene Expression Regulation Neoplastic Oncology Immunology Cancer cell Cancer research Female ELISA business NODAL Breast Neoplasm Cyclin-Dependent Kinase Inhibitor p27 V600E Human Priority Research Paper medicine.drug |
| Zdroj: | Oncotarget |
| ISSN: | 1949-2553 |
| DOI: | 10.18632/oncotarget.6049 |
| Popis: | Nodal is highly expressed in various human malignancies, thus supporting the rationale for exploring Nodal as a therapeutic target. Here, we describe the effects of a novel monoclonal antibody (mAb), 3D1, raised against human Nodal. In vitro treatment of C8161 human melanoma cells with 3D1 mAb shows reductions in anchorage-independent growth and vasculogenic network formation. 3D1 treated cells also show decreases of Nodal and downstream signaling molecules, P-Smad2 and P-ERK and of P-H3 and CyclinB1, with an increase in p27. Similar effects were previously reported in human breast cancer cells where Nodal expression was generally down-regulated; following 3D1 mAb treatment, both Nodal and P-H3 levels are reduced. Noteworthy is the reduced growth of human melanoma xenografts in Nude mice treated with 3D1 mAb, where immunostaining of representative tumor sections show diminished P-Smad2 expression. Similar effects both in vitro and in vivo were observed in 3D1 treated A375SM melanoma cells harboring the active BRAF(V600E) mutation compared to treatments with IgG control or a BRAF inhibitor, dabrafenib. Finally, we describe a 3D1-based ELISA for the detection of Nodal in serum samples from cancer patients. These data suggest the potential of 3D1 mAb for selecting and targeting Nodal expressing cancers. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|